Commenting on these results, ProMIS President and CEO, Dr. Elliot Goldstein, stated: "Our latest data lend further support to the potential best in class profile of PMN310.
We previously reported greater selectivity and binding of humanized PMN310 for toxic, amyloid beta (A beta) oligomers in direct comparison to other amyloid beta-directed antibodies, including aducanumab."
Aged mice were studied to assess and compare the ability of humanized PMN310 (huPMN310) and aducanumab to cross the blood brain barrier (BBB) and penetrate the CNS.
617 901-0785Dr. Elliot GoldsteinPresident and Chief Executive Officer, ProMIS Neurosciences Inc.Tel.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: ProMIS Neurosciences via Globenewswire
Posts published in “Business”
Sign this petition and tell Big Pharma not to abandon the Alzheimer's research we desperately need.
Sadly, Pfizer has just announced that it is shutting down all research programs for neurological disorders like Alzheimer's disease and Parkinson's disease [3].
This decision will result in hundreds of layoffs and one fewer potential route toward an Alzheimer's cure.
Pfizer and other pharmaceutical companies must not abandon such work that is critical to finding a cure for Alzheimer's disease.
Sign the petition and demand that they continue their vital Alzheimer's research programs.